Indoco Remedies
Ticker > Company >

Indoco Remedies share price

Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs  68.66 K   137   18

299.15
-5.00 (-1.64%)
BSE: 17 Sep 04:01 PM

Price Summary

Today's High

₹ 312.55

Today's Low

₹ 298.5

52 Week High

₹ 383.55

52 Week Low

₹ 190

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2759.6 Cr.

Enterprise Value

₹ 3485.55 Cr.

No. of Shares

9.22 Cr.

P/E

0

P/B

2.58

Face Value

₹ 2

Div. Yield

0.07 %

Book Value (TTM)

₹  115.94

CASH

₹ 12.03 Cr.

DEBT

₹ 737.99 Cr.

Promoter Holding

58.9 %

EPS (TTM)

₹  -5.61

Sales Growth

-15.22%

ROE

-0.79 %

ROCE

2.84%

Profit Growth

-107.49 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Indoco Remedies Ltd.

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-15.22%
3 Year-0.47%
5 Year6.54%

Profit Growth

1 Year-107.49%
3 Year-138.38%
5 Year-181.53%

ROE%

1 Year-0.79%
3 Year8.24%
5 Year11.19%

ROCE %

1 Year2.84%
3 Year11.05%
5 Year14.41%

Debt/Equity

0.6724

Price to Cash Flow

30.4

Interest Cover Ratio

0.8698

CFO/PAT (5 Yr. Avg.)

1.41494382391583

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 58.90 0.00
Mar 2025 58.90 0.00
Dec 2024 58.80 0.00
Sep 2024 58.75 0.00
Jun 2024 58.75 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 65.391 days.
  • The company has a high promoter holding of 58.9%.

 Limitations

  • The company has shown a poor profit growth of -138.378811247785% for the Past 3 years.
  • The company has shown a poor revenue growth of -0.468227062666271% for the Past 3 years.
  • Company has low Interest coverage ratio of 0.8698.
  • Company has contingent liabilities of 392.1208 Cr.
  • The company is trading at a high EV/EBITDA of 31.1655.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 401.43 396.53 372.98 347.25 392.53
Total Expenditure 349.86 343.66 352.84 343.79 377.7
Operating Profit 51.57 52.87 20.14 3.46 14.83
Other Income 3.52 4.2 4.26 6.5 5.58
Interest 11.88 14.77 14 15.98 23.61
Depreciation 23.7 24.92 24.75 24.88 25.2
Exceptional Items 0 0 0.99 0 0
Profit Before Tax 19.51 17.38 -13.36 -30.9 -28.4
Tax 4.56 4.59 -3.13 -4.66 -0.34
Profit After Tax 14.95 12.79 -10.23 -26.24 -28.06
Adjusted EPS (Rs) 1.62 1.39 -1.11 -2.84 -3.04

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1240.3 1539.72 1666.69 1790.81 1518.19
Total Expenditure 1022.67 1213.81 1381.85 1540.71 1390.16
Operating Profit 217.63 325.91 284.84 250.1 128.03
Other Income 9.05 6.71 2.62 17.38 18.48
Interest 22.22 17.43 25.27 37.8 56.63
Depreciation 73.12 78.95 70.6 87.98 98.25
Exceptional Items 0 0 0 11.53 0.99
Profit Before Tax 131.35 236.23 191.59 153.23 -7.38
Tax 38.96 81.71 50.23 36.58 1.36
Net Profit 92.39 154.52 141.36 116.64 -8.74
Adjusted EPS (Rs.) 10.03 16.77 15.34 12.65 -0.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.44 18.45
Total Reserves 750.5 885.87 1008.59 1108.18 1084.91
Borrowings 96.94 95.88 143.5 203.6 336.89
Other N/C liabilities 61.36 60.68 61.91 68.14 65.9
Current liabilities 408.54 519.93 483.21 595.03 695.01
Total Liabilities 1335.76 1580.8 1715.64 1993.38 2201.16
Assets
Net Block 569.91 554.98 661.46 732.34 754.38
Capital WIP 25.12 52.82 54.36 92.5 181.37
Intangible WIP 42.98 68.72 58.21 21.94 44.42
Investments 2.45 2.46 18.9 51.96 51.96
Loans & Advances 71.29 33.68 52.03 154.87 207.26
Other N/C Assets 2.05 2.13 2.25 6.78 6.3
Current Assets 621.95 866.01 868.44 932.99 955.47
Total Assets 1335.76 1580.8 1715.64 1993.38 2201.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 131.35 236.23 191.59 141.7 -8.37
Adjustment 109.71 87.12 120.88 130.08 147.22
Changes in Assets & Liabilities -139.14 -108.81 -72.29 -77.42 -32.49
Tax Paid -19.75 -40.99 -61.38 -29.1 -16.6
Operating Cash Flow 82.17 173.55 178.79 176.78 90.77
Investing Cash Flow -66.7 -121.41 -208.51 -301.7 -259.79
Financing Cash Flow -29.83 -44.37 22.81 122.4 168.62
Net Cash Flow -14.35 7.77 -6.91 -2.52 -0.41

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 58.75 58.75 58.80 58.90 58.90
kare aruna suresh 5.20 5.20 5.20 5.20 5.20
kare suresh govind 4.40 4.40 4.40 4.40 4.40
madhura suresh kare 5.65 5.65 5.65 5.68 5.68
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
megh milind panandikar 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 0.01 0.01 0.01 0.01
panandikar aditi milind 6.08 6.08 6.13 6.14 6.14
pooja rajendra pai - - - 0.01 0.01
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.11 17.11 17.11 17.19 17.19
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
spa holdings pvt ltd 19.89 19.89 19.89 19.88 19.88
suresh govind kare huf (k... - 0.30 0.30 0.30 0.30
sudha m pai 0.01 0.01 0.01 - -
suresh govind kare (huf) ... 0.30 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 41.25 41.25 41.20 41.10 41.10
dsp healthcare fund 2.27 2.52 3.91 3.98 4.01
franklin india smaller co... 1.48 1.48 1.48 2.20 2.20
hdfc value fund - - - 1.67 1.67
independent director - 0.01 - - 0.01
investor education and pr... 0.11 0.11 0.18 - 0.18
llp 0.07 0.09 0.12 0.15 0.12
mangeshi investment priva... 1.27 1.27 - 1.27 1.27
nippon life india trustee... - - - - 4.80
quant mutual fund -quant ... - - - - 4.55
tata india pharma & healt... - - 1.32 1.32 1.32
investor education and pr... - - - 0.18 -
nippon life india trustee... 4.97 4.97 4.81 4.80 -
quant mutual fund - quant... 4.56 4.56 4.56 4.55 -
hdfc trustee company ltd.... - 1.67 1.67 - -
mangeshi investmentprivat... - - 1.27 - -
icici prudential smallcap... 1.79 1.14 - - -
hdfc trustee company ltd ... 1.45 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research Ventura
Research HDFC Securities
Research Nirmal Bang
Research Prabhudas Lilladhar

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY25
Concall Q1FY24
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY22

Company News

Indoco Remedies informs about disclosure 30 Aug, 11:00 AM Indoco Remedies gets final nod for Rivaroxaban Tablets 13 Aug, 12:00 PM Indoco Remedies informs about earnings call transcript 28 Jul, 5:34 PM Indoco Remedies - Quaterly Results 24 Jul, 12:02 PM Indoco Remedies - Quaterly Results 24 Jul, 12:02 PM Indoco Remedies - Quaterly Results 24 Jul, 12:02 PM Indoco Remedies gets Certificate of EU GMP Compliance for sterile drug product manufacturing facility in Goa 24 Jul, 10:21 AM Indoco Remedies informs about certificate 24 Jul, 9:52 AM Indoco Remedies’ arm launches Ticagrelor film-coated tablets in UK 3 Jun, 3:21 PM Indoco Remedies gets USFDA’s final approval for Allopurinol Tablets 23 May, 12:44 PM Indoco Remedies - Quaterly Results 22 May, 2:36 PM Indoco Remedies - Quaterly Results 22 May, 2:36 PM Indoco Remedies - Quaterly Results 22 May, 2:36 PM Indoco Remedies informs about disclosure 21 Mar, 2:43 PM Indoco Remedies’ AnaCipher completes 5-day comprehensive USFDA inspection 10 Mar, 5:22 PM Indoco Remedies informs about press release 10 Mar, 5:15 PM Indoco Remedies informs about disclosures 10 Mar, 4:44 PM Indoco Remedies informs about disclosure 25 Feb, 12:23 PM Indoco Remedies informs about disclosure 11 Feb, 11:14 AM Indoco Remedies informs about disclosure 11 Feb, 10:37 AM Indoco Remedies - Quaterly Results 21 Jan, 12:28 PM Indoco Remedies - Quaterly Results 21 Jan, 12:28 PM Indoco Remedies - Quaterly Results 21 Jan, 12:28 PM Indoco Remedies informs about allotment of equity shares under ESOP 21 Jan, 11:48 AM Indoco Remedies informs about compliances-certificate 7 Jan, 5:17 PM Indoco Remedies informs about closure of trading window 30 Dec, 2:38 PM Indoco Remedies informs about disclosure 17 Dec, 3:17 PM Indoco Remedies gets warning letter for Goa facility 17 Dec, 2:25 PM Indoco Remedies informs about investors meet 10 Dec, 5:18 PM Indoco Remedies informs about disclosure 3 Dec, 10:27 AM Indoco Remedies enters into strategic distribution partnership with Clarity Pharma, UK 2 Dec, 5:34 PM Indoco Remedies informs about disclosure 27 Nov, 5:39 PM Indoco Remedies informs about disclosure 19 Nov, 5:32 PM Indoco Remedies gets final ANDA approval from USFDA for Varenicline Tablets 30 Oct, 2:26 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies gets USFDA’s approval for Cetirizine Hydrochloride Tablets 4 Oct, 3:08 PM Indoco Remedies informs about press release 4 Oct, 1:41 PM Indoco Remedies informs about disclosure 26 Aug, 5:27 PM Indoco Remedies gets USFDA’s final approval for Lofexidine Tablets 21 Aug, 2:58 PM USFDA inspects Indoco Remedies’ manufacturing facilities in Goa 27 Jul, 3:55 PM Indoco Remedies informs about disclosure 26 Jul, 11:07 AM Indoco Remedies informs about press release 24 Jul, 5:00 PM Indoco Remedies informs about outcome of board meeting 23 Jul, 4:58 PM Indoco Remedies reports 92% fall in Q1 consolidated net profit 23 Jul, 3:55 PM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies informs about board meeting 10 Jul, 4:57 PM

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Indoco Remedies. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Indoco Remedies has a PE ratio of -53.4517187277136 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Indoco Remedies has ROA of -0.4165% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Indoco Remedies has a Current ratio of 1.3748.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Indoco Remedies has a ROE of -0.7867%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Indoco Remedies has a Debt to Equity ratio of 0.6724 which means that the company has low proportion of debt in its capital.

  • Sales growth: Indoco Remedies has reported revenue growth of -15.2232% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Indoco Remedies for the current financial year is 8.43318863237338%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Indoco Remedies is Rs 0.2 and the yield is 0.0667%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Indoco Remedies is Rs -5.6088. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Indoco Remedies in Ticker for free. Also, one can get the intrinsic value of Indoco Remedies by using Valuation Calculators, which are available with a Finology ONE subscription. 

Indoco Remedies FAQs

Q1. What is Indoco Remedies share price today?
Ans: The current share price of Indoco Remedies is Rs 299.8.

Q2. What is the market capitalisation of Indoco Remedies?
Ans: Indoco Remedies has a market capitalisation of Rs 2765.5921919 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Indoco Remedies?
Ans: The PE ratio of Indoco Remedies is -53.4517187277136 and the P/B ratio of Indoco Remedies is 2.58572881241909, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Indoco Remedies share?
Ans: The 52-week high share price of Indoco Remedies is Rs 383, and the 52-week low share price of Indoco Remedies is Rs 190.

Q5. Does Indoco Remedies pay dividends?
Ans: Currently, Indoco Remedies pays dividends. Dividend yield of Indoco Remedies is around 0.0667%.

Q6. What are the face value and book value of Indoco Remedies shares?
Ans: The face value of Indoco Remedies shares is Rs 2, while the book value per share of Indoco Remedies is around Rs 115.9441. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Indoco Remedies?
Ans: Indoco Remedies has a total debt of Rs 737.9905 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Indoco Remedies?
Ans: The ROE of Indoco Remedies is -0.7867% and ROCE of Indoco Remedies is 2.8433%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Indoco Remedies a good buy for the long term?
Ans: The Indoco Remedies long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Indoco Remedies undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Indoco Remedies appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Indoco Remedies’s financials?
Ans: You can review Indoco Remedies’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Indoco Remedies

Indoco Remedies Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Indoco Remedies Ltd. is a renowned pharmaceutical company with a strong presence in both domestic and international markets. With a legacy spanning several decades, the company has established itself as a key player in the pharmaceutical industry. Indoco Remedies Ltd. is known for its commitment to quality and innovation, and it operates across various therapeutic segments such as cardiovascular, anti-infectives, pain management, and more.

Indoco Remedies Ltd. - Share Price

The share price of Indoco Remedies Ltd. reflects the market's perception of the company's value and potential. Investors keen on analyzing the stock can track the share price using our pre-built screening tool, which provides real-time updates and historical data. By monitoring the share price, investors can identify trends, patterns, and potential buying or selling opportunities.

Indoco Remedies Ltd. - Balance Sheet

The balance sheet of Indoco Remedies Ltd. is a crucial financial statement that provides insights into the company's financial position. Investors can examine the company's assets, liabilities, and equity recorded on the balance sheet. To aid in the stock analysis process, our website offers premium features such as fair value calculations using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Indoco Remedies Ltd. - Annual Report

The annual report of Indoco Remedies Ltd. offers a comprehensive overview of the company's performance and achievements over the past year. It provides detailed information on the company's financials, operations, strategic initiatives, and future outlook. Investors can download the annual report from our website to gain an in-depth understanding of Indoco Remedies Ltd.'s progress and prospects.

Indoco Remedies Ltd. - Dividend

Dividends are an important consideration for long-term stock investors. Indoco Remedies Ltd. has a track record of rewarding its shareholders through regular dividend payouts. By analyzing the company's dividend history and policies, investors can gauge the company's commitment to sharing profits with its shareholders.

Indoco Remedies Ltd. - Quarterly Result

Keeping track of Indoco Remedies Ltd.'s quarterly results is essential for investors looking for timely and relevant information. Our website provides access to the company's quarterly reports, allowing investors to assess the company's performance, revenue, and profitability on a regular basis. Combining these reports with our pre-built screening tools can facilitate effective stock analysis.

Indoco Remedies Ltd. - Stock Price

Indoco Remedies Ltd.'s stock price is a dynamic indicator of market sentiment and investor perception. By analyzing historical stock price data and monitoring market trends, investors can identify potential trading opportunities. Our website offers real-time stock price updates, interactive price charts, and news to help investors make informed decisions.

Indoco Remedies Ltd. - Price Chart

Visual representation of Indoco Remedies Ltd.'s stock price movements can be insightful for investors. Our website features interactive price charts that enable users to track historical price trends, identify patterns, and analyze market behavior. Combined with our pre-built screening tools, investors can leverage price charts to enhance their stock analysis and decision-making.

Indoco Remedies Ltd. - News

Staying updated with the latest news and developments surrounding Indoco Remedies Ltd. is crucial for informed decision-making. Our website curates news articles and press releases related to the company, enabling investors to stay on top of industry trends, regulatory changes, product launches, and other market influences. Accessing relevant news can provide valuable insights for stock analysis.

Indoco Remedies Ltd. - Concall Transcripts

Concall transcripts offer detailed records of earnings conference calls conducted by Indoco Remedies Ltd. By accessing these transcripts through our website, investors gain access to management discussions, insights, and future guidance. These insights combined with our pre-built screening tools can enhance stock analysis and aid in understanding the company's strategic outlook.

Indoco Remedies Ltd. - Investor Presentations

Investor presentations provide a comprehensive overview of Indoco Remedies Ltd.'s business strategies, financial performance, and growth potential. By studying investor presentations available for download on our website, investors can gain deeper insights into the company's value proposition, market positioning, and future plans. Access to these presentations enhances the stock analysis process.

Indoco Remedies Ltd. - Promoters

Indoco Remedies Ltd. owes its success to its dedicated promoters. The promoters play a significant role in shaping the company's growth and strategy. Investors can evaluate the credibility and track record of the promoters to gain insights into the company's leadership and long-term vision.

Indoco Remedies Ltd. - Shareholders

Understanding the shareholders and their holdings in Indoco Remedies Ltd. can provide insights into the company's ownership structure and potential influence. Investors can analyze the shareholding patterns and identify key stakeholders who have a significant interest in the company. Such analysis can aid in evaluating the company's stability and potential for growth.

Remember, for detailed financial data points, numbers, and analyses, we recommend referring to the downloadable annual reports, concall transcripts, investor presentations, credit ratings, and research reports available on our website. Our premium features, such as fair value calculation tools, can further enhance your stock analysis. Stay abreast of the latest news, track the share price, and leverage our pre-built screening tools for a comprehensive analysis of Indoco Remedies Ltd.'s stock. 

Indoco Remedies Balance Sheet Overview

Analyzing the financial stability and growth trajectory of Indoco Remedies, the balance sheet data reveals significant insights.

Indoco Remedies Reserves Growth

Between March 2020 and March 2024, Indoco Remedies demonstrated a steady increase in total reserves, from Rs 661.73 Cr in March 2020 to a robust Rs 1,108.18 Cr by March 2024. This reflects the company's ability to reinvest and support future expansion.

Indoco Remedies Debt Evolution

Indoco Remedies' borrowings showed a gradual rise from Rs 96.93 Cr in March 2020 to Rs 203.60 Cr in March 2024. This incremental debt suggests strategic leverage, possibly for growth financing or capital investments.

Indoco Remedies Asset Buildup

Total assets of Indoco Remedies surged from Rs 1,240.24 Cr in March 2020 to Rs 1,993.38 Cr by March 2024, highlighting an escalating asset base. Notably, the net block increased from Rs 589.62 Cr to Rs 732.34 Cr, reflecting capital accumulation and infrastructural investments.

Indoco Remedies Current Asset Position

The company's current assets climbed from Rs 561.76 Cr in March 2020 to Rs 932.99 Cr in March 2024. This commendable development indicates improved liquidity and working capital management over the years.

The presented data offers a standalone analysis of Indoco Remedies' balance sheet. For investors monitoring the pharmaceutical sector, such balance sheet analyses can complement other stock screening tools to inform investment decisions.

Note: All figures are in Rs Cr. and the analysis pertains to the standalone balance sheet of Indoco Remedies.

Read More
X